Market Overview:
The global insomnia medication market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as the increasing prevalence of insomnia, rising awareness about available treatments, and growing demand for better-quality sleep. The global insomnia medication market is segmented on the basis of type into nonbenzodiazepine receptor agonists, benzodiazepine receptor agonists, and selective melatonin receptor agonist ramelteon. The nonbenzodiazepine receptor agonist segment is expected to grow at a CAGR of 6% from 2018 to 2030 due to its high efficacy and safety profile. The benzodiazepine receptor agonist segment is projected to grow at a CAGR of 4% during the forecast period owing to its long-standing use for treating insomnia. Ramelteon is expected to be the fastest-growing segment in the global insomnia medication market during the forecast period owing its superior efficacy and safety profile over other medications used for treating insomnia. On the basis of application, adults are estimated account for majority share in terms revenue generated by sales through prescription drugs followed by kids segments respectively during 2017 &2027 .
Product Definition:
Insomnia Medication is a type of medication prescribed to individuals who have difficulty sleeping. It can help promote sleep and improve sleep quality. Insomnia Medication is typically used on a short-term basis, and it should not be used regularly for long periods of time.
Nonbenzodiazepine Receptor Agonists:
Nonbenzodiazepine receptor agonists are a new class of drug that was introduced in the market after the benzodiazepines were taken off. They are used as anti-anxiety agents and sleep aids. The nonbenzodiazepine drugs have been approved by Health Canada for treatment of insomnia, which is a major factor driving their growth in this market.
Benzodiazepine Receptor Agonists:
Benzodiazepine receptor agonists are a new class of drugs for the treatment of insomnia. They were introduced in the market after 5-HT3 receptor antagonists lost patent exclusivity. The main target for this drug is benzodiazepine (BZ) receptors, which are located primarily in the brain stem. These drugs produce an improvement in sleep architecture by decreasing rapid eye movement (REM) sleep and increasing slow wave sleep (SWS).
Application Insights:
Adults accounted for the largest share of over 70.0% in 2017 owing to higher prevalence of insomnia disorder among adults as compared to other age groups. According to a survey conducted by the National Sleep Foundation, nearly 40-50 million Americans suffer from chronic sleeplessness and it is estimated that around 20 million adult patients suffer from some form of insomnia each year. The Selective Melatonin Receptor Agonist (SELMA) ramelteon is anticipated to be one of the most prescribed drugs for treating Insomnia in adults during the forecast period due primarily on its high efficacy and low side effects when compared with benzodiazepine or nonbenzodiazepine receptor agonists available in market at present time.
The kid's application segment was valued over USD 120 million in 2017 owing mainly on high incidence rate of primary school children suffering from Insomnia Disorder which may be attributed largely on improper sleeping habits formed early during their life thus forming a good foundation for academic performance.
Regional Analysis:
North America dominated the global insomnia medication market in 2017. The presence of a large number of manufacturers and suppliers coupled with high healthcare expenditure, awareness about sleep disorders, and availability of effective treatment methods are some factors attributing to its largest share. In addition, the region is expected to maintain its position during the forecast period due to continuous launch of novel drugs by companies such as Takeda Pharmaceuticals U.S.A., Inc.; Dr Reddy's Laboratories; Cipla Inc.; Sun Pharma USA; Shire US; Mylan N.V.
The American Sleep Association offers an online resource for patients that provides information regarding diagnosis and treatment options for both adults.
Growth Factors:
- Increasing awareness about the benefits of insomnia medication among people.
- Rising prevalence of sleep disorders and chronic insomnia.
- Growing demand for prescription and over-the-counter drugs for the treatment of insomnia.
- Technological advancements in the field of sleep medicine that are helping to improve diagnosis and treatment options for patients with sleep disorders, including chronic insomnia 5 Increased investment by pharmaceutical companies in research and development activities aimed at developing new drugs for the treatment of insomnia
Scope Of The Report
Report Attributes
Report Details
Report Title
Insomnia Medication Market Research Report
By Type
Nonbenzodiazepine Receptor Agonists, Benzodiazepine Receptor Agonists, The Selective Melatonin Receptor Agonist Ramelteon, Sedating Antidepressants
By Application
Adults, Kids
By Companies
Eisai, Merck, Pfizer, Sanofi, Takeda, Vanda Pharmaceuticals, Astellas, Dainippon Sumitomo, ECR Pharmaceuticals (Valeant), Flynn Pharma, Johnson & Johnson, Meda, Somnus Therapeutics, Purdue Pharma, Neurim, Minerva Neurosciences, Pernix Therapeutics, SkyePharma, Paratek Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Insomnia Medication Market Report Segments:
The global Insomnia Medication market is segmented on the basis of:
Types
Nonbenzodiazepine Receptor Agonists, Benzodiazepine Receptor Agonists, The Selective Melatonin Receptor Agonist Ramelteon, Sedating Antidepressants
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Kids
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eisai
- Merck
- Pfizer
- Sanofi
- Takeda
- Vanda Pharmaceuticals
- Astellas
- Dainippon Sumitomo
- ECR Pharmaceuticals (Valeant)
- Flynn Pharma
- Johnson & Johnson
- Meda
- Somnus Therapeutics
- Purdue Pharma
- Neurim
- Minerva Neurosciences
- Pernix Therapeutics
- SkyePharma
- Paratek Pharmaceuticals
Highlights of The Insomnia Medication Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nonbenzodiazepine Receptor Agonists
- Benzodiazepine Receptor Agonists
- The Selective Melatonin Receptor Agonist Ramelteon
- Sedating Antidepressants
- By Application:
- Adults
- Kids
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Insomnia Medication Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Insomnia medication is a type of medication that helps people to fall asleep and stay asleep. It can be used in combination with other treatments, such as sleep counseling, to help improve the quality of sleep for people who have difficulty sleeping.
Some of the key players operating in the insomnia medication market are Eisai, Merck, Pfizer, Sanofi, Takeda, Vanda Pharmaceuticals, Astellas, Dainippon Sumitomo, ECR Pharmaceuticals (Valeant), Flynn Pharma, Johnson & Johnson, Meda, Somnus Therapeutics, Purdue Pharma, Neurim, Minerva Neurosciences, Pernix Therapeutics, SkyePharma, Paratek Pharmaceuticals.
The insomnia medication market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Insomnia Medication Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Insomnia Medication Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Insomnia Medication Market - Supply Chain
4.5. Global Insomnia Medication Market Forecast
4.5.1. Insomnia Medication Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Insomnia Medication Market Size (000 Units) and Y-o-Y Growth
4.5.3. Insomnia Medication Market Absolute $ Opportunity
5. Global Insomnia Medication Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Insomnia Medication Market Size and Volume Forecast by Type
5.3.1. Nonbenzodiazepine Receptor Agonists
5.3.2. Benzodiazepine Receptor Agonists
5.3.3. The Selective Melatonin Receptor Agonist Ramelteon
5.3.4. Sedating Antidepressants
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Insomnia Medication Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Insomnia Medication Market Size and Volume Forecast by Application
6.3.1. Adults
6.3.2. Kids
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Insomnia Medication Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Insomnia Medication Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Insomnia Medication Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Insomnia Medication Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Insomnia Medication Demand Share Forecast, 2019-2029
9. North America Insomnia Medication Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Insomnia Medication Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Insomnia Medication Market Size and Volume Forecast by Application
9.4.1. Adults
9.4.2. Kids
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Insomnia Medication Market Size and Volume Forecast by Type
9.7.1. Nonbenzodiazepine Receptor Agonists
9.7.2. Benzodiazepine Receptor Agonists
9.7.3. The Selective Melatonin Receptor Agonist Ramelteon
9.7.4. Sedating Antidepressants
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Insomnia Medication Demand Share Forecast, 2019-2029
10. Latin America Insomnia Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Insomnia Medication Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Insomnia Medication Market Size and Volume Forecast by Application
10.4.1. Adults
10.4.2. Kids
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Insomnia Medication Market Size and Volume Forecast by Type
10.7.1. Nonbenzodiazepine Receptor Agonists
10.7.2. Benzodiazepine Receptor Agonists
10.7.3. The Selective Melatonin Receptor Agonist Ramelteon
10.7.4. Sedating Antidepressants
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Insomnia Medication Demand Share Forecast, 2019-2029
11. Europe Insomnia Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Insomnia Medication Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Insomnia Medication Market Size and Volume Forecast by Application
11.4.1. Adults
11.4.2. Kids
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Insomnia Medication Market Size and Volume Forecast by Type
11.7.1. Nonbenzodiazepine Receptor Agonists
11.7.2. Benzodiazepine Receptor Agonists
11.7.3. The Selective Melatonin Receptor Agonist Ramelteon
11.7.4. Sedating Antidepressants
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Insomnia Medication Demand Share, 2019-2029
12. Asia Pacific Insomnia Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Insomnia Medication Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Insomnia Medication Market Size and Volume Forecast by Application
12.4.1. Adults
12.4.2. Kids
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Insomnia Medication Market Size and Volume Forecast by Type
12.7.1. Nonbenzodiazepine Receptor Agonists
12.7.2. Benzodiazepine Receptor Agonists
12.7.3. The Selective Melatonin Receptor Agonist Ramelteon
12.7.4. Sedating Antidepressants
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Insomnia Medication Demand Share, 2019-2029
13. Middle East & Africa Insomnia Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Insomnia Medication Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Insomnia Medication Market Size and Volume Forecast by Application
13.4.1. Adults
13.4.2. Kids
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Insomnia Medication Market Size and Volume Forecast by Type
13.7.1. Nonbenzodiazepine Receptor Agonists
13.7.2. Benzodiazepine Receptor Agonists
13.7.3. The Selective Melatonin Receptor Agonist Ramelteon
13.7.4. Sedating Antidepressants
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Insomnia Medication Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Insomnia Medication Market: Market Share Analysis
14.2. Insomnia Medication Distributors and Customers
14.3. Insomnia Medication Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Eisai
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Takeda
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Vanda Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Astellas
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Dainippon Sumitomo
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. ECR Pharmaceuticals (Valeant)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Flynn Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Johnson & Johnson
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Meda
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Somnus Therapeutics
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Purdue Pharma
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Neurim
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Minerva Neurosciences
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Pernix Therapeutics
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. SkyePharma
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Paratek Pharmaceuticals
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
